We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Aerie Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 153 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 156 → 0 (-156)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $703M → $0 (-$703M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 153

Holders
–
Holders Change
-156
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
153
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$73.5M
2
BlackRock
BlackRock
New York
-$53.6M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$36.9M
4
UBS Group
UBS Group
Switzerland
-$36.4M
5
WIC
Water Island Capital
New York
-$31.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Los Angeles Capital Management
51
Los Angeles Capital Management
California
– -$1.76M -116,560 Closed
Ameriprise
52
Ameriprise
Minnesota
– -$1.76M -116,422 Closed
Swiss National Bank
53
Swiss National Bank
Switzerland
– -$1.57M -103,800 Closed
DAM
54
DLD Asset Management
New York
– -$1.51M -100,000 Closed
Two Sigma Advisers
55
Two Sigma Advisers
New York
– -$1.48M -97,900 Closed
Nordea Investment Management
56
Nordea Investment Management
Sweden
– -$1.34M -88,766 Closed
PCM
57
Prelude Capital Management
New York
– -$1.26M -83,004 Closed
RhumbLine Advisers
58
RhumbLine Advisers
Massachusetts
– -$1.2M -79,568 Closed
TIM
59
Thompson Investment Management
Wisconsin
– -$1.13M -74,712 Closed
AGM
60
Alpine Global Management
New York
– -$1.09M -71,825 Closed
SG Americas Securities
61
SG Americas Securities
New York
– -$1.05M -69,385 Closed
AllianceBernstein
62
AllianceBernstein
Tennessee
– -$1.05M -69,300 Closed
Walleye Capital
63
Walleye Capital
New York
– -$1.02M -67,310 Closed
BCM
64
BCK Capital Management
Connecticut
– -$968K -64,000 Closed
New York State Common Retirement Fund
65
New York State Common Retirement Fund
New York
– -$924K -61,094 Closed
CANY
66
Caxton Associates (New York)
New York
– -$923K -60,974 Closed
PP
67
PDT Partners
New York
– -$910K -60,164 Closed
Prudential Financial
68
Prudential Financial
New Jersey
– -$894K -59,040 Closed
California State Teachers Retirement System (CalSTRS)
69
California State Teachers Retirement System (CalSTRS)
California
– -$854K -56,433 Closed
UBS AM
70
UBS AM
Illinois
– -$810K -53,554 Closed
CC
71
Centiva Capital
New York
– -$757K -50,000 Closed
HM
72
Harvest Management
New York
– -$757K -50,000 Closed
SEI Investments
73
SEI Investments
Pennsylvania
– -$743K -49,059 Closed
Tudor Investment Corp
74
Tudor Investment Corp
Connecticut
– -$739K -48,874 Closed
Squarepoint
75
Squarepoint
New York
– -$724K -47,884 Closed
1 2
3
4 5

AERI Hedge Fund Activity: Q4 2022 in Review

0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2022, worth a combined $0 — down 100% from $703M a quarter earlier.

Sellers outnumbered buyers: 153 funds closed out of AERI and 0 opened new positions — a net loss of 153 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Deerfield Management, exiting entirely with an estimated $73.5M sold.

  • 0 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2022, down from 156 in Q3 2022.
  • Funds reported $0 of Aerie Pharmaceuticals stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Aerie Pharmaceuticals positions in Q4 2022 and 153 closed out, a net change of -153 holders.
  • The largest Aerie Pharmaceuticals seller in Q4 2022 was Deerfield Management, an estimated $73.5M sold.

Based on aggregated 13F filings for Q4 2022.